Company intelligence / Profile preview
ILGEN
Syracuse, New York, United Statesilgenbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ILGEN has developed a proprietary platform to rapidly generate and select high-affinity, fully human monoclonal antibodies for therapeutic and diagnostic use. Their approach significantly reduces the time required to obtain validated antibody candidates compared to traditional methods. The company’s pipeline includes an anti-LAG3 antibody program and a human fusion protein (ILG-F), with applications in cancer, autoimmune, infectious, vascular, and lymphoproliferative diseases. No published clinical results are available as of now[1][3].
- Therapeutic areas
- CardiovascularRheumatologyImmunologyHematologyOncologyInfectious Diseases
- Modalities
- Fully human monoclonal antibodiesFusion proteins (e.g., human fusion protein ILG-F)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on ILGEN.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ILGEN.